Bio Pharma Dive
APRIL 14, 2022
Fresh trial results intensify competition with Roche to deliver the first lymphoma drug that marries antibody technology with an immunotherapy pathway.
World of DTC Marketing
APRIL 14, 2022
Over 70% of people have been exposed to medical or health-related misinformation. Of those exposed, almost half are not confident in their ability to discriminate between accurate health information and misinformation. Social media is cited as the most common source of misinformation. People on the right use social media to purposely hurt family members who lost loved ones to Covid.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
APRIL 14, 2022
A third shot sparked a strong immune response in clinical testing, positioning the companies to make boosters available to the roughly 28 million kids in the U.S. who became eligible for their first two doses late last year.
BioPharma Reporter
APRIL 14, 2022
Pfizer is set to acquire Australiaâs ResApp - a company developing a smartphone app to detect COVID-19 and other respiratory diseases based on the userâs cough - for $100m AUD ($74m USD).
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
APRIL 14, 2022
A little more than a year after taking on the role, Jim Mullen is preparing to pass the torch to Gilmore O'Neill, who has served as the chief medical officer at Sarepta Therapeutics.
Scienmag
APRIL 14, 2022
In a Policy Forum, Anna Lewis and colleagues argue that, for researchers and others who want to invoke genetic ancestry, there is a scientific and ethical imperative to move away from continental ancestry categories and to instead embrace a view of genetic ancestry that reflects continuous variation and historical depth. Such change is a “prerequisite […].
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Patent Watch
APRIL 14, 2022
Annual Drug Patent Expirations for ARISTADA Aristada is a drug marketed by Alkermes Inc and is included in two NDAs. It is available from one supplier. There are fifteen patents…. The post New patent for Alkermes Inc drug ARISTADA appeared first on DrugPatentWatch - Make Better Decisions.
XTalks
APRIL 14, 2022
In this video, Xtalks spoke with Intertek Alchemy’s Laura Dunn Nelson, Vice President of Food Safety and Global Alliances. Laura spoke about her role at Intertek Alchemy and shared the most rewarding aspects of her work. Xtalks also asked Laura to discuss the challenges that companies are having today with their food safety culture. Laura has more than 30 years of experience implementing food safety and quality control programs for packaging, processing, retail operations and food service.
Scienmag
APRIL 14, 2022
THE University of Huddersfield has forged a partnership with an innovative technology business to work with Network Rail on developing a safer and more reliable track lubrication measurement system. Credit: University of Huddersfield THE University of Huddersfield has forged a partnership with an innovative technology business to work with Network Rail on developing a safer […].
BioPharma Reporter
APRIL 14, 2022
The US agencyâs latest draft document lays out guidelines to help increase involvement of underrepresented ethnic and racial populations in clinical research.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Scienmag
APRIL 14, 2022
A new data-driven mechanistic approach that predicts cell types within tissue will help to reduce drug costs and treat diseases that were difficult to develop drugs for, according to a West Virginia University scientist. Credit: West Virginia University A new data-driven mechanistic approach that predicts cell types within tissue will help to reduce drug costs […].
Pharma Times
APRIL 14, 2022
Approval demonstrates significant step forward in the treatment of adult advanced NSCLC patients with METex14
Scienmag
APRIL 14, 2022
In a study to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal (23-26 April), researchers from Sociedade Mineira de Infectologia and Associação Mineira de Epidemiologia e Controle de Infecções show a correlation between the Brazilian President Jair Bolsonaro’s denialist attitude to COVID-19 and higher COVID-19 incidence […].
pharmaphorum
APRIL 14, 2022
The massive backlog in patient care across Europe resulting from the pandemic will take at least three years to clear and in some cases as long as six years, says a new study. The research from Censuswide stems from surveys of oncologists and surgeons across six European countries, which found that 20% of them estimate clearing the backlog will take between four and six years.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Scienmag
APRIL 14, 2022
An international team of environmental scientists have published a series of significant recommendations to protect, conserve and study the world’s coral reefs – the ‘canaries in the coal mine’ of climate change. Credit: Tom Vierus © WCS An international team of environmental scientists have published a series of significant recommendations to protect, conserve and study […].
pharmaphorum
APRIL 14, 2022
Pfizer’s Australian unit has tabled an offer to buy ResApp Health and its smartphone apps for the management and diagnosis of respiratory diseases in a deal that values the digital health company at around A$100 million (around $75 million). Pfizer is offering A$0.115 per share in cash for ResApp, a deal which has been accepted by the company’s directors and recommended to shareholders ahead of a vote scheduled in June.
Scienmag
APRIL 14, 2022
Toronto – A paper co-authored by Prof. Ruben Gaetani of the University of Toronto is the recipient of the 2021 Austin Robinson Memorial Prize from the Royal Economic Society. The prize is awarded annually for the best paper published in The Economic Journal by authors who are within five years of receiving their PhDs.’ Credit: […].
Pharma Times
APRIL 14, 2022
Trial of Amplivant will begin in a number of cancer patients including those with ovarian cancer
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Scienmag
APRIL 14, 2022
Similar to the widespread interest in “graphite” and “diamond,” there is growing interest in metastable phases, which have different physical properties than those of stable phases. However, processes to fabricate metastable-phase materials are highly limited. Novel findings have been published about the development of a new metastable-phase synthesis method, which can drastically improve the physical […].
pharmaphorum
APRIL 14, 2022
Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead drug in the partnership – epcoritamab for large B-cell lymphoma (LBCL). The drugmaker has reported top-line results from the phase 1/2 EPCORE trial of epcoritamab as a third-line therapy for relapsed/refractory LBCL, revealing an overall response rate of 63% and a median duration of response of 12 months.
Scienmag
APRIL 14, 2022
In early September 2020, severe winds, high heat, and prolonged drought conditions led to the explosive growth of wildfires along the western slopes of the Cascades Mountains in the Pacific Northwest. The fires engulfed enormous tracts of forestland, destroyed communities, took dozen of lives, and cost hundreds of millions to fight. Credit: Cody Evers In […].
pharmaphorum
APRIL 14, 2022
US cost-effectiveness watchdog ICER has handed bluebird bio some good news ahead of its FDA advisory committee meeting for rare blood disorder gene therapy beti-cel in June, by endorsing its proposed $2.1 million price tag. ICER’s assessment is still at the draft stage and could be changed after an ongoing comment period, but will be welcomed by bluebird and other gene therapy developers as they try to set a price for their one-shot treatments that will be accepted by payers.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Scienmag
APRIL 14, 2022
Light on, light off – this is how one could describe the behavior of the nova, which goes by the name RS Ophiuchi (RS Oph). Every 15 years or so, a dramatic explosion occurs in the constellation of the Serpent Bearer. Birthplaces of a nova are systems in which two very different stars live in […].
Drug Patent Watch
APRIL 14, 2022
Annual Drug Patent Expirations for AIRDUO+DIGIHALER Airduo Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are twenty-two…. The post New patent for Teva Pharm drug AIRDUO DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
APRIL 14, 2022
Nearly 12 years after the Deepwater Horizon oil spill, scientists are still examining the potential health effects on workers and volunteers who experienced oil-related exposures. Credit: Submitted Photo/NIEHS Nearly 12 years after the Deepwater Horizon oil spill, scientists are still examining the potential health effects on workers and volunteers who experienced oil-related exposures.
Drug Patent Watch
APRIL 14, 2022
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are sixteen…. The post New patent for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Scienmag
APRIL 14, 2022
Scientists at Trinity College Dublin have announced a significant advance in our understanding of epilepsy, as they have identified a potential method of preventing damaging seizure activity. Credit: Trinity College Dublin Scientists at Trinity College Dublin have announced a significant advance in our understanding of epilepsy, as they have identified a potential method of preventing damaging seizure […].
Drug Patent Watch
APRIL 14, 2022
Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
APRIL 14, 2022
A new University of Gothenburg study has paved the way for the first drug treatment for sleep apnea. Compared to before receiving the treatment, breathing pauses decreased with on average more than 20 per hour for patients given the drug. Credit: Photo by Johan Wingborg A new University of Gothenburg study has paved the way […].
Drug Patent Watch
APRIL 14, 2022
Annual Drug Patent Expirations for ARISTADA+INITIO+KIT Aristada Initio Kit is a drug marketed by Alkermes Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Alkermes Inc drug ARISTADA INITIO KIT appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
361 
Let's personalize your content